These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 10480415)
1. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Hsu DH; Shi JD; Homola M; Rowell TJ; Moran J; Levitt D; Druilhet B; Chinn J; Bullock C; Klingbeil C Transplantation; 1999 Aug; 68(4):545-54. PubMed ID: 10480415 [TBL] [Abstract][Full Text] [Related]
2. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Norman DJ; Vincenti F; de Mattos AM; Barry JM; Levitt DJ; Wedel NI; Maia M; Light SE Transplantation; 2000 Dec; 70(12):1707-12. PubMed ID: 11152101 [TBL] [Abstract][Full Text] [Related]
4. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. Cole MS; Anasetti C; Tso JY J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161 [TBL] [Abstract][Full Text] [Related]
5. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473 [TBL] [Abstract][Full Text] [Related]
6. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells. Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559 [TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362 [TBL] [Abstract][Full Text] [Related]
8. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. Carpenter PA; Pavlovic S; Tso JY; Press OW; Gooley T; Yu XZ; Anasetti C J Immunol; 2000 Dec; 165(11):6205-13. PubMed ID: 11086054 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. Bonnefoy-Berard N; Revillard JP J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497 [TBL] [Abstract][Full Text] [Related]
10. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice. Weetall M; Digan ME; Hugo R; Mathew S; Hopf C; Tart-Risher N; Zhang J; Shi V; Fu F; Hammond-McKibben D; West S; Brack R; Brinkmann V; Bergman R; Neville D; Lake P Transplantation; 2002 May; 73(10):1658-66. PubMed ID: 12042656 [TBL] [Abstract][Full Text] [Related]
11. HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Chau LA; Tso JY; Melrose J; Madrenas J Transplantation; 2001 Apr; 71(7):941-50. PubMed ID: 11349730 [TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of five humanized OKT3 effector function variant antibodies. Xu D; Alegre ML; Varga SS; Rothermel AL; Collins AM; Pulito VL; Hanna LS; Dolan KP; Parren PW; Bluestone JA; Jolliffe LK; Zivin RA Cell Immunol; 2000 Feb; 200(1):16-26. PubMed ID: 10716879 [TBL] [Abstract][Full Text] [Related]
13. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Anderson D; Chambers K; Hanna N; Leonard J; Reff M; Newman R; Baldoni J; Dunleavy D; Reddy M; Sweet R; Truneh A Clin Immunol Immunopathol; 1997 Jul; 84(1):73-84. PubMed ID: 9191886 [TBL] [Abstract][Full Text] [Related]
16. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Schlereth B; Quadt C; Dreier T; Kufer P; Lorenczewski G; Prang N; Brandl C; Lippold S; Cobb K; Brasky K; Leo E; Bargou R; Murthy K; Baeuerle PA Cancer Immunol Immunother; 2006 May; 55(5):503-14. PubMed ID: 16032400 [TBL] [Abstract][Full Text] [Related]
17. A humanised mouse model of cytokine release: comparison of CD3-specific antibody fragments. Malcolm SL; Smith EL; Bourne T; Shaw S J Immunol Methods; 2012 Oct; 384(1-2):33-42. PubMed ID: 22796190 [TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594 [TBL] [Abstract][Full Text] [Related]
19. Role of CD18-dependent and CD18-independent mechanisms in the increased leukocyte adhesiveness and in the variations of circulating white blood cell populations induced by anti-CD3 monoclonal antibodies. Kinnaert P; Pradier O; Bournonville B; Habrant C; Goldman M; Van Geertruyden N Transpl Int; 1996; 9(4):386-91. PubMed ID: 8819275 [TBL] [Abstract][Full Text] [Related]